학술논문
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial
Document Type
Article
Author
Matthews, Gail; Jacoby, Simone; Borok, Margaret; Eriobu, Nnakelu; Kaplan, Richard; Kumarasamy, Nagalingeswaran; Bennet, Jaclyn Ann; Avihingsanon, Anchalee; Chetchotisakd, Ploenchan; Wagner Cardoso, Sandra; Azwa, Iskander; Losso, Marcelo; Brown, Dannae; Arlinda, Dona; Hutchinson, Jolie; Kelleher, Anthony; Cisse, Mohamed; Dao, Sounkalo; Polizzotto, Mark; Emery, Sean; Law, Matthew; Papot, Emmanuelle; Karyana, Muhammad; Lupo, Sergio; Solari, Ana Melisa; Grinsztejn, Beatriz; Wolff, Marcello; Andrade-Villanueva, Jaime; Mosqueda Gómez, Juan Luis; Chow, Ting Soo; Mohapi, Lerato; Yunihastuti, Evy; Hadi, Usman; Katu, Sudirman; Subronto, Yanri Wijayanti; Lane, H. Clifford; Perelis, Leonardo
Source
The Lancet HIV; 20240101, Issue: Preprints
Subject
Language
ISSN
24054704; 23523018
Abstract
Randomised comparative data on efficacy and safety of second-line antiretroviral therapy (ART) after failure of non-nucleoside reverse transcriptase inhibitors (NNRTIs) across diverse geographical settings are scarce. The aim of this study was to evaluate optimal second-line ART for people with HIV.